Quality, economics, and national guidelines for transcatheter aortic valve replacement

Peter M. Pollak, Michael J. Mack, David Holmes

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Transcatheter aortic valve replacement (TAVR) is a transformative technology for the treatment of aortic stenosis, requiring a multidisciplinary collaboration in the form of a "heart team" that includes interventional cardiologists and cardiac surgeons. As this new technology continues to disperse rapidly, its proper therapeutic role evolves and leads to important questions regarding who should perform the procedure, where it should be performed, and who should pay for it. Herein, we review the most recent guidelines governing the use of TAVR in the United States and Europe. We then summarize the available registry data, which, despite its limitations, presents the clearest picture of TAVR in clinical use. Finally, we discuss the costs and relative cost-effectiveness of TAVR. Taken together, these are the elements from which the larger questions surrounding TAVR must be answered.

Original languageEnglish (US)
Pages (from-to)610-618
Number of pages9
JournalProgress in Cardiovascular Diseases
Volume56
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Economics
Guidelines
Technology
Aortic Valve Stenosis
Cost-Benefit Analysis
Registries
Transcatheter Aortic Valve Replacement
Costs and Cost Analysis
Therapeutics

Keywords

  • Aortic stenosis
  • Cost
  • Cost-effectiveness
  • National guidelines
  • Quality
  • Transcatheter aortic valve replacement

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Quality, economics, and national guidelines for transcatheter aortic valve replacement. / Pollak, Peter M.; Mack, Michael J.; Holmes, David.

In: Progress in Cardiovascular Diseases, Vol. 56, No. 6, 2014, p. 610-618.

Research output: Contribution to journalArticle

@article{e539bfff3b4849fc9e8e0c7286bc2af7,
title = "Quality, economics, and national guidelines for transcatheter aortic valve replacement",
abstract = "Transcatheter aortic valve replacement (TAVR) is a transformative technology for the treatment of aortic stenosis, requiring a multidisciplinary collaboration in the form of a {"}heart team{"} that includes interventional cardiologists and cardiac surgeons. As this new technology continues to disperse rapidly, its proper therapeutic role evolves and leads to important questions regarding who should perform the procedure, where it should be performed, and who should pay for it. Herein, we review the most recent guidelines governing the use of TAVR in the United States and Europe. We then summarize the available registry data, which, despite its limitations, presents the clearest picture of TAVR in clinical use. Finally, we discuss the costs and relative cost-effectiveness of TAVR. Taken together, these are the elements from which the larger questions surrounding TAVR must be answered.",
keywords = "Aortic stenosis, Cost, Cost-effectiveness, National guidelines, Quality, Transcatheter aortic valve replacement",
author = "Pollak, {Peter M.} and Mack, {Michael J.} and David Holmes",
year = "2014",
doi = "10.1016/j.pcad.2014.03.001",
language = "English (US)",
volume = "56",
pages = "610--618",
journal = "Progress in Cardiovascular Diseases",
issn = "0033-0620",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Quality, economics, and national guidelines for transcatheter aortic valve replacement

AU - Pollak, Peter M.

AU - Mack, Michael J.

AU - Holmes, David

PY - 2014

Y1 - 2014

N2 - Transcatheter aortic valve replacement (TAVR) is a transformative technology for the treatment of aortic stenosis, requiring a multidisciplinary collaboration in the form of a "heart team" that includes interventional cardiologists and cardiac surgeons. As this new technology continues to disperse rapidly, its proper therapeutic role evolves and leads to important questions regarding who should perform the procedure, where it should be performed, and who should pay for it. Herein, we review the most recent guidelines governing the use of TAVR in the United States and Europe. We then summarize the available registry data, which, despite its limitations, presents the clearest picture of TAVR in clinical use. Finally, we discuss the costs and relative cost-effectiveness of TAVR. Taken together, these are the elements from which the larger questions surrounding TAVR must be answered.

AB - Transcatheter aortic valve replacement (TAVR) is a transformative technology for the treatment of aortic stenosis, requiring a multidisciplinary collaboration in the form of a "heart team" that includes interventional cardiologists and cardiac surgeons. As this new technology continues to disperse rapidly, its proper therapeutic role evolves and leads to important questions regarding who should perform the procedure, where it should be performed, and who should pay for it. Herein, we review the most recent guidelines governing the use of TAVR in the United States and Europe. We then summarize the available registry data, which, despite its limitations, presents the clearest picture of TAVR in clinical use. Finally, we discuss the costs and relative cost-effectiveness of TAVR. Taken together, these are the elements from which the larger questions surrounding TAVR must be answered.

KW - Aortic stenosis

KW - Cost

KW - Cost-effectiveness

KW - National guidelines

KW - Quality

KW - Transcatheter aortic valve replacement

UR - http://www.scopus.com/inward/record.url?scp=84900026602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900026602&partnerID=8YFLogxK

U2 - 10.1016/j.pcad.2014.03.001

DO - 10.1016/j.pcad.2014.03.001

M3 - Article

C2 - 24838136

AN - SCOPUS:84900026602

VL - 56

SP - 610

EP - 618

JO - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

SN - 0033-0620

IS - 6

ER -